Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration. Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning its product Gelrin C as a smart investment in what it terms “cartilage economics,” targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions.
Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows. With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis aims to capture a significant share of this market by offering a 10-minute procedure that uses a synthetic material to support tissue regeneration without the need for cell harvesting or culturing.
What begins as a localized cartilage defect can ultimately evolve into a significant clinical and economic challenge. Unlike many tissues in the body, articular cartilage has little ability to regenerate on its own, leaving untreated lesions vulnerable to progressive deterioration that may culminate in osteoarthritis (“OA”). The company emphasizes that intervening early with products like Gelrin C could reduce the long-term burden of OA, which accounts for a substantial portion of the $15 billion annual spending gap.
Today, advances in regenerative medicine are creating new opportunities to address cartilage damage more effectively and efficiently. Regentis’ approach leverages a hydrogel that is implanted during a straightforward procedure, potentially reducing recovery times and costs compared to more invasive surgeries or biologic treatments that require complex logistics. The company believes that Gelrin C’s off-the-shelf availability and ease of use could make it a preferred option for surgeons and patients alike.
The announcement comes as part of a broader marketing campaign by Regentis, which is listed on the NYSE American under the ticker RGNT. The company has engaged IBN, a communications platform, to disseminate information about Gelrin C through various channels, including press releases and social media. According to the terms of the engagement, IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage. This content was disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid marketing engagement with IBN.
Investors and stakeholders are encouraged to review the latest news and updates relating to RGNT, available in the company’s newsroom at ibn.fm/RGNT. For more information about BioMedWire, the platform that distributed this content, visit https://www.BioMedWire.com. Full terms of use and disclaimers applicable to all content provided by BMW are available at https://www.BioMedWire.com/Disclaimer.
While Gelrin C is not yet approved by the U.S. Food and Drug Administration, Regentis is conducting clinical trials to demonstrate its safety and efficacy. If successful, the product could offer a new tool in the fight against knee osteoarthritis, potentially reducing the economic and personal toll of this debilitating condition.
